Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases
Siddharth Singh, Herbert C. Heien, Jeph Herrin, Parambir S. Dulai, Lindsey R. Sangaralingham, Nilay D. Shah, William J. Sandborn
Topics & Concepts
VedolizumabMedicineInflammatory Bowel DiseasesInternal medicineTumor necrosis factor alphaInflammatory bowel diseaseUstekinumabGastroenterologyTumor necrosis factorsUlcerative colitisInfliximabDiseaseInflammatory Bowel DiseaseRheumatoid Arthritis Research and TherapiesBiosimilars and Bioanalytical Methods